At Dren Bio, we are committed to developing novel therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. We do this through engineered antibodies designed to selectively engage a patient’s own immune system for targeted depletion of diseased cells or agents. At present, our therapies are considered investigational, which means that they have not been approved as safe and effective by regulatory health authorities.
Providing patients access to our investigational treatments through an expanded access program (also referred to as compassionate use) is a complex matter to which we have given much thought. We believe that the most appropriate access to our investigational agents is through participation in our ongoing clinical trials because this offers the best means to ensure the safe use of our investigational products and to generate the necessary data for product approval by regulatory agencies. Therefore, we do not plan to offer expanded access at this time. If you should have an interest in participating in one of our clinical trials, please consult with your treating physician based on the up-to-date information listed on clinicaltrials.gov ( NCT05475925 ).
We will continue to evaluate our expanded access policy on an ongoing basis. Should changes be made, we will update this website accordingly.